• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification.

作者信息

Wijnenga Maarten M J, Dubbink Hendrikus J, French Pim J, Synhaeve Nathalie E, Dinjens Winand N M, Atmodimedjo Peggy N, Kros Johan M, Dirven Clemens M F, Vincent Arnaud J P E, van den Bent Martin J

机构信息

Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute, PO Box 5201, 3008AE, Rotterdam, The Netherlands.

Department of Pathology, Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

出版信息

Acta Neuropathol. 2017 Dec;134(6):957-959. doi: 10.1007/s00401-017-1781-z. Epub 2017 Oct 19.

DOI:10.1007/s00401-017-1781-z
PMID:29052002
Abstract
摘要

相似文献

1
Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification.成人弥漫性低级别异柠檬酸脱氢酶（IDH）野生型胶质瘤的分子与临床异质性：端粒酶逆转录酶（TERT）启动子突变以及7号和10号染色体拷贝数状态的评估可实现更优的预后分层。
Acta Neuropathol. 2017 Dec;134(6):957-959. doi: 10.1007/s00401-017-1781-z. Epub 2017 Oct 19.
2
Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.在 IDH 突变型和 IDH 野生型弥漫性胶质瘤中，使用端粒酶启动子突变来标记具有相互临床行为的特定分子亚群。
J Neurosurg. 2018 Apr;128(4):1102-1114. doi: 10.3171/2016.11.JNS16973. Epub 2017 Jun 16.
3
TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.TERT 启动子突变及其与胶质瘤中 IDH 突变的相互作用：TERT 启动子和 IDH 突变的联合将低级别胶质瘤分为不同的生存亚组——基于汇总数据的荟萃分析。
Crit Rev Oncol Hematol. 2017 Dec;120:1-9. doi: 10.1016/j.critrevonc.2017.09.013. Epub 2017 Oct 3.
4
TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.端粒酶逆转录酶（TERT）启动子突变有助于异柠檬酸脱氢酶（IDH）突变预测世界卫生组织（WHO）二级和三级弥漫性胶质瘤对辅助治疗的不同反应。
Oncotarget. 2015 Sep 22;6(28):24871-83. doi: 10.18632/oncotarget.4549.
5
Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.端粒酶逆转录酶（TERT）启动子突变对弥漫性胶质瘤中异柠檬酸脱氢酶（IDH）突变和O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子甲基化的临床意义
Pathol Res Pract. 2018 Jun;214(6):881-888. doi: 10.1016/j.prp.2018.04.002. Epub 2018 Apr 5.
6
TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.端粒酶逆转录酶（TERT）启动子突变的世界卫生组织（WHO）二级和三级胶质瘤优先位于额叶且避开中线。
Int J Clin Exp Pathol. 2015 Sep 1;8(9):11485-94. eCollection 2015.
7
Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.根据 2021 年世界卫生组织中枢神经系统肿瘤分类对成人弥漫性胶质瘤进行分级。
Lab Invest. 2022 Feb;102(2):126-133. doi: 10.1038/s41374-021-00667-6. Epub 2021 Sep 9.
8
TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.胶质瘤中的端粒酶逆转录酶（TERT）启动子突变、遗传关联及临床病理相关性
Br J Cancer. 2014 Nov 11;111(10):2024-32. doi: 10.1038/bjc.2014.538. Epub 2014 Oct 14.
9
Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II-III gliomas to establish genetic predictors of poor prognosis.对 IDH 野生型 WHO 分级 II-III 级胶质瘤进行临床、组织病理学和分子分析，以确定预后不良的遗传预测因子。
Brain Tumor Pathol. 2019 Oct;36(4):135-143. doi: 10.1007/s10014-019-00348-9. Epub 2019 Jul 19.
10
Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas.根据异柠檬酸脱氢酶（IDH）和端粒酶逆转录酶（TERT）启动子突变分类的胶质瘤组在原发性和复发性胶质瘤中保持稳定。
Neuro Oncol. 2017 Jul 1;19(7):1008-1010. doi: 10.1093/neuonc/nox042.

引用本文的文献

1
Analysis of clinical, histological, and genomic information of molecular glioblastoma in a Japanese glioma cohort.日本胶质瘤队列中分子胶质母细胞瘤的临床、组织学和基因组信息分析。
Brain Tumor Pathol. 2025 Apr 6. doi: 10.1007/s10014-025-00500-8.
2
A Radiologist's Guide to IDH-Wildtype Glioblastoma for Efficient Communication With Clinicians: Part I-Essential Information on Preoperative and Immediate Postoperative Imaging.放射科医生与临床医生有效沟通的异柠檬酸脱氢酶野生型胶质母细胞瘤指南：第一部分——术前及术后即刻影像学的基本信息
Korean J Radiol. 2025 Mar;26(3):246-268. doi: 10.3348/kjr.2024.0982.
3
Clinical characteristics, molecular reclassification trajectories and DNA methylation patterns of long- and short-term survivors of WHO grade II and III glioma.
世界卫生组织二级和三级神经胶质瘤长期和短期幸存者的临床特征、分子重新分类轨迹及DNA甲基化模式
J Neurol. 2025 Feb 15;272(3):210. doi: 10.1007/s00415-025-12923-6.
4
Management of Low-Grade Gliomas.低级别胶质瘤的管理
Cancer J. 2025;31(1). doi: 10.1097/PPO.0000000000000760.
5
Comparative analysis of molecular and histological glioblastomas: insights into prognostic variance.分子与组织学胶质母细胞瘤的对比分析：对预后差异的深入了解。
J Neurooncol. 2024 Sep;169(3):531-541. doi: 10.1007/s11060-024-04737-9. Epub 2024 Aug 8.
6
Exploring molecular glioblastoma: Insights from advanced imaging for a nuanced understanding of the molecularly defined malignant biology.探索分子胶质母细胞瘤：先进成像技术带来的见解，以细致入微地理解分子定义的恶性生物学特性。
Neurooncol Adv. 2024 Jul 4;6(1):vdae106. doi: 10.1093/noajnl/vdae106. eCollection 2024 Jan-Dec.
7
Diffuse, IDH-wildtype gliomas in adults with minimal histological change and isolated TERT promoter mutation: not simply CNS WHO grade 4.成人中具有最小组织学变化和孤立TERT启动子突变的弥漫性、异柠檬酸脱氢酶（IDH）野生型胶质瘤：并非简单的中枢神经系统世界卫生组织4级。
Acta Neuropathol. 2024 Jul 29;148(1):12. doi: 10.1007/s00401-024-02773-3.
8
Molecular diversity in isocitrate dehydrogenase-wild-type glioblastoma.异柠檬酸脱氢酶野生型胶质母细胞瘤中的分子多样性
Brain Commun. 2024 Mar 27;6(2):fcae108. doi: 10.1093/braincomms/fcae108. eCollection 2024.
9
Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.IDH1/2 野生型中枢神经系统 WHO 分级 4 级胶质瘤的治疗结果，这些肿瘤组织学上诊断为 WHO 分级 II 级或 III 级星形细胞瘤。
J Neurooncol. 2024 Mar;167(1):133-144. doi: 10.1007/s11060-024-04585-7. Epub 2024 Feb 7.
10
Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting.荷兰高级成人弥漫性神经胶质瘤的下一代测序：原发性诊断和复发性检测中的实验室间差异。
J Neurooncol. 2024 Feb;166(3):485-492. doi: 10.1007/s11060-024-04568-8. Epub 2024 Jan 29.